Literature DB >> 22270323

Evaluation of IPPSE, an alternative method for sequential population PKPD analysis.

B D Lacroix1, L E Friberg, M O Karlsson.   

Abstract

The aim of this study is to present and evaluate an alternative sequential method to perform population pharmacokinetic-pharmacodynamic (PKPD) analysis. Simultaneous PKPD analysis (SIM) is generally considered the reference method but may be computationally burdensome and time consuming. Evaluation of alternative approaches aims at speeding up the computation time and stabilizing the estimation of the models, while estimating the model parameters with good enough precision. The IPPSE method presented here uses the individual PK parameter estimates and their uncertainty (SE) to propagate the PK information to the PD estimation step, while the IPP method uses the individual PK parameters only and the PPP&D method utilizes the PK data. Data sets (n = 200) with various study designs were simulated according to a one-compartment PK model and a direct Emax PD model. The study design of each dataset was randomly selected. The same PK and PD models were fitted to the simulated observations using the SIM, IPP, PPP&D and IPPSE methods. The performances of the methods were compared with respect to estimation precision and bias, and computation time. Estimated precision and bias for the IPPSE method were similar to that of SIM and PPP&D, while IPP had higher bias and imprecision. Compared with the SIM method, IPPSE saved more computation time (61%) than PPP&D (39%), while IPP remained the fastest method (86% run time saved). The IPPSE method is a promising alternative for PKPD analysis, combining the advantages of the SIM (higher precision and lower bias of parameter estimates) and the IPP (shorter run time) methods.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22270323     DOI: 10.1007/s10928-012-9240-x

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  5 in total

1.  Population modelling in drug development.

Authors:  L Sheiner; J Wakefield
Journal:  Stat Methods Med Res       Date:  1999-09       Impact factor: 3.021

2.  Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

Review 3.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

4.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

5.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

  5 in total
  13 in total

1.  Modelling the dose-response relationship: the fair share of pharmacokinetic and pharmacodynamic information.

Authors:  Mario González-Sales; Fahima Nekka; Mario Tanguay; Pierre-Olivier Tremblay; Jun Li
Journal:  Br J Clin Pharmacol       Date:  2017-02-14       Impact factor: 4.335

2.  The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.

Authors:  Ida Netterberg; Mats O Karlsson; Elisabet I Nielsen; Angelica L Quartino; Henrik Lindman; Lena E Friberg
Journal:  Br J Clin Pharmacol       Date:  2018-01-18       Impact factor: 4.335

3.  Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer.

Authors:  Chiara Zecchin; Ivelina Gueorguieva; Nathan H Enas; Lena E Friberg
Journal:  Br J Clin Pharmacol       Date:  2016-06-08       Impact factor: 4.335

4.  Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake.

Authors:  B Guiastrennec; D P Sonne; M Hansen; J I Bagger; A Lund; J F Rehfeld; O Alskär; M O Karlsson; T Vilsbøll; F K Knop; M Bergstrand
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-12

5.  A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.

Authors:  E Schindler; M A Amantea; M O Karlsson; L E Friberg
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-05-26

6.  Morphine Pharmacodynamics in Mechanically Ventilated Preterm Neonates Undergoing Endotracheal Suctioning.

Authors:  P A Välitalo; E H Krekels; M van Dijk; Shp Simons; D Tibboel; C A Knibbe
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-01-21

7.  A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory.

Authors:  Emilie Schindler; Lena E Friberg; Bertram L Lum; Bei Wang; Angelica Quartino; Chunze Li; Sandhya Girish; Jin Y Jin; Mats O Karlsson
Journal:  Pharm Res       Date:  2018-04-19       Impact factor: 4.200

8.  Standard Error of Empirical Bayes Estimate in NONMEM® VI.

Authors:  Dongwoo Kang; Kyun-Seop Bae; Brett E Houk; Radojka M Savic; Mats O Karlsson
Journal:  Korean J Physiol Pharmacol       Date:  2012-04-24       Impact factor: 2.016

Review 9.  HCV Kinetic Models and Their Implications in Drug Development.

Authors:  Tht Nguyen; J Guedj
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-04-17

10.  Inter occasion variability in individual optimal design.

Authors:  Anders N Kristoffersson; Lena E Friberg; Joakim Nyberg
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-10-01       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.